MedX Health Corp. Announces Postponement of the Release of Second Quarter Interim Financial Statements and Related Disclosure Due to COVID-19 Related Delays
TORONTO--(BUSINESS WIRE)-- MedX Health Corp. (MDX: TSXV) (“the Company”), announces that there will be a delay in the filing of its Interim Financial Statements and accompanying Management’s Discussion and Analysis, and related CEO and CFO certifications for the Second Quarter ended June 30, 2020 (collectively "Interim Filings") due to COVID-19 related delays.
On May 20, 2020, the Canadian Securities Administrators (CSA) announced that they will provide issuers with a 45-day filing extension for filings required during the period from June 2, 2020 to August 31, 2020, to allow issuers the time needed to focus on the many other business and financial reporting implications of COVID-19. The Company will rely on this exemption with respect to the Interim Filings in accordance with Ontario Instrument 51-505, Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to August 31, 2020 and corresponding Instruments in the other jurisdictions in which the Company is a reporting issuer.
The Company is continuing to work diligently and expeditiously towards filing the Interim Filings by no later than September 25, 2020. In the interim, Management and other insiders of the Company are subject to a trading black-out policy that reflects the principles in section 9 of National Policy 11-207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Rob von der Porten, Chairman and Acting CEO
MedX Health Corp
Source: MedX Health Corp.